|
Sign In to gain access to subscriptions and/or personal tools.
|
The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion
Marc S Weinberg
Division of Nephrology, Roger Williams Medical Center, Boston University School of Medicine Affiliate, Providence, RI 02904 USA, KininMD{at}aol.com
Adam J Weinberg
Division of Nephrology, Roger Williams Medical Center, Boston University School of Medicine Affiliate, Providence, RI 02904 USA
Raymond Cord
Division of Nephrology, Roger Williams Medical Center, Boston University School of Medicine Affiliate, Providence, RI 02904 USA
Dion H Zappe
Division of Nephrology, Roger Williams Medical Center, Boston University School of Medicine Affiliate, Providence, RI 02904 USA
The optimal doses of angiotensin-converting enzyme inhibitors (ACE-I) and/or angiotensin II receptor blockers (ARBs) for maximal reduction in urinary protein excretion are not known. Moreover, beneficial effects from ARBs, such as tissue protection owing to a more complete blockade of the renin-angiotensin-aldosterone system (RAAS), may be independent of blood pressure-lowering by ARBs. In this investigation, we evaluated whether increasing the dose of candesartan cilexetil, in subjects already on the maximally-recommended FDA doses of 32 mg, would induce a further reduction in 24-hour urinary protein excretion in patients with heavy proteinuria (urinary protein excretion >1.5 g/day; mean 4.4±2 g/day). Ten patients were started on 16 or 32 mg of candesartan cilexetil daily. After 1—2 months of therapy, the dose was titrated upwards to 96 mg. In all subjects, there were further reductions in 24-hour urinary protein excretion when the dose was increased beyond the recommended 32 mg maximal dose. Increasing the dose of candesartan cilexetil to 96 mg was safe, as most subjects showed no changes in serum potassium and, as expected, only a slight increase (0.5—0.7 mg/dl) in serum creatinine. These data warrant further investigation, since some subjects may require higher doses of candesartan to achieve optimal regression of proteinuria.
Key Words: renin-angiotensin system • proteinuria • AT1-receptor antagonists • ACE inhibitors • heavy proteinuria
References
- Remuzzi G. Nephropathic nature of proteinuria. Curr Opin Nephrol Hypertens 1999;8(6):655-63.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- De Jong PE, Navis G., de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999;354(9176):352-3.[CrossRef][Medline]
[Order article via Infotrieve]
- Bakris GL, Slataper R., Vicknair N., Sadler R. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications 1994; 8(1):2-6.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Gansevoort RT, de Zeeuw D., de Jong PE Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45(3):861-7. 5. Andersen S., Tarnow L., Rossing P., Hansen BV, Parving HH Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57(2):601-6.[CrossRef]
- Weinberg MS, Weinberg AJ, Zappe DH Effectively targeting the renin-angiotensin system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin converting enzyme-inhibitors. JRAAS 2000;1(3):217-33.[Medline]
[Order article via Infotrieve]
- Hollenberg NK, Fisher NDL, Price DA Pathways for angiotensin II generation in intact human tissue. Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-92.[Abstract/Free Full Text]
- Mooser V., Nussberger J., Juillerat L. et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990;15(2): 276-82.[Web of Science][Medline]
[Order article via Infotrieve]
- Weir MR Impact of salt intake on blood pressure and proteinuria in diabetes: importance of the renin-angiotensin system. Miner Electrolyte Metab 1998;24(6):438-45.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Peters H., Ritz E. Dosing angiotensin II blockers - beyond blood pressure. Nephrol Dial Transplant 1999;14:2568-70.[Free Full Text]
Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 1 suppl,
S196-S198 (2001)
DOI: 10.1177/14703203010020013401
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Burgess, N. Muirhead, P. R. de Cotret, A. Chiu, V. Pichette, S. Tobe, and the SMART (Supra Maximal Atacand Renal Trial) Inve
Supramaximal Dose of Candesartan in Proteinuric Renal Disease
J. Am. Soc. Nephrol.,
April 1, 2009;
20(4):
893 - 900.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Schmieder, A. U. Klingbeil, E. H. Fleischmann, R. Veelken, and C. Delles
Additional Antiproteinuric Effect of Ultrahigh Dose Candesartan: A Double-Blind, Randomized, Prospective Study
J. Am. Soc. Nephrol.,
October 1, 2005;
16(10):
3038 - 3045.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. K. Hollenberg
Treatment of the Patient With Diabetes Mellitus and Risk of Nephropathy: What Do We Know, and What Do We Need to Learn?
Arch Intern Med,
January 26, 2004;
164(2):
125 - 130.
[Full Text]
[PDF]
|
|
|
|
|
